New recommendations in prostate cancer screening and treatment

Journal of the American Academy of Physician Assistants

Volumn 27, Issue 8, 2014, Pages 14-20

  Adams, Lisa K ^a   Ferrington, Lindsay S ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University PA Program   (United States)

Author keywords

Androgen deprivation therapy; Gleason score; Prostate cancer; Prostate specifi C antigen; Screening; Vaccine

Indexed keywords

AGED; EARLY CANCER DIAGNOSIS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATIENT PARTICIPATION; PRACTICE GUIDELINE; PROSTATIC NEOPLASMS;

AGED; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; PATIENT PARTICIPATION; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS;

EID: 84905102047     PISSN: 15471896     EISSN: 08937400     Source Type: Journal    
DOI: 10.1097/01.JAA.0000451872.86566.bf     Document Type: Article

References (38)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29
2. MacVicar GR, Hussain MH. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol. 2013;25(3):252-260
3. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241
4. Chou R, Croswell J, Dana T, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155(11):762-771
5. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134
6. Brown M. AAFP, USPSTF issue fi nal recommendation against routine PSA-based screening for prostate cancer. American Academy of Family Physicians: Health of the Public. 2012. http://www.aafp.org/news-now/health-of-The-public/ 20120522 psascreenrec.html. Accessed December 4, 2013
7. Harris G. Panel's advice on prostate test sets up battle. New York Times. http://www.nytimes.com/2011/10/08/health/policy/08prostate.html. October 7, 2011. Accessed December 4, 2013
8. Gomella LG, Liu XS, Trabulsi EJ, et al. Screening for prostate cancer: The current evidence and guidelines controversy. Can J Urol. 2011;18(5):5875-5883
9. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. 2013. http://www.auanet.org/common/pdf/education/ clinical-guidance/Prostate-Cancer-Detection.pdf
10. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specifi c antigen at age 40-55 and long term risk of metastasis: Casecontrol study. BMJ. 2013;346:f2023
11. Weight CJ, Kim SP, Jacobson DJ, et al. Men (aged 40-49 years) with a single baseline prostate-specifi c antigen below 1.0 ng/mL have a very low long-Term risk of prostate cancer: Results from a prospectively screened population cohort. Urology. 2013;82(6): 1211-1217
12. Starkman JR, Milam DF, Smith JA. Men's health topics. In: Andreoli TE, Benjamin IJ, Griggs RC, Wing EJ, eds. Andreoli and Carpenter's Cecil Essentials of Medicine, 8th ed. Philadelphia, PA: Saunders/Elsevier; 2010:763-765
13. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011; 71(9):985-997
14. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol. 2004;22(11):2141-2149
15. Drudge-Coates L, Turner B. Prostate cancer overview. Part 1: Non-metastatic disease. Br J Nurs. 2012;21(9):S23-S28
16. Meng MV. Cancers of the genitourinary tract. In: McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. 50th ed. New York: McGraw Hill Medical; 2011:1564-1569
17. Chang RT, Kirby R, Challacombe BJ. Is there a link between BPH and prostate cancer?. Practitioner. 2012;256(1750):13-16
18. Lieberman R. Evidence-based medical perspectives: The evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of effi cacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther. 2004;11(6):501-506
19. Agabegi SS, Agabegi ED. Step-up to Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008
20. Loeb S, Metter EJ, Kan D, et al. Prostate-specifi c antigen velocity (PSAV) risk count improves the specifi city of screening for clinically signifi cant prostate cancer. BJU Int. 2012;109(4):508-514
21. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol. 2012; 187(3):795-801
22. Pinto F, Totaro A, Palermo G, et al. Imaging in prostate cancer staging: Present role and future perspectives. Urol Int. 2012;88(2):125-136
23. Tombal B, Lecouvet F. Modern detection of prostate cancer's bone metastasis: Is the bone scan era over?. Adv Urol. 2012;2012
24. De Nunzio C, Leonardo C, Franco G, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: External validation of a novel risk stratifi cation tool. World J Urol. 2013;31(2):365-369
25. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM Classifi cation of Malignant Tumors. 7th ed. Hoboken, New Jersey: Wiley-Blackwell; 2009
26. Dahabreh IJ, Chung M, Balk EM, et al. Active surveillance in men with localized prostate cancer: A systematic review. Ann Intern Med. 2012;156(8):582-590
27. Wolff JM, Mason M. Drivers for change in the management of prostate cancer-guidelines and new treatment techniques. BJU Int. 2012;109(suppl 6):33-41
28. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specifi c antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109(suppl 1):22-29
29. Hale Z, Miyake M, Palacios DA, Rosser CJ. Focal cryosurgical ablation of the prostate: A single institute's perspective. BMC Urol. 2013;13:2
30. Sartor AO, Fitzpatrick JM. Urologists and oncologists: Adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110(3):328-335
31. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002;(1):CD003506
32. Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012;14(2):204-221
33. Spencer S, Marini BL, Figg WD. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res. 2012;32(7): 2391-2398
34. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws-characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg. 2012;40(4):303-309
35. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082-3092
36. Nilsson S, Franzen L, Parker C, et al. Bone-Targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587-594
37. Kelly WK, Halabi S, Carducci M, et al. Randomized, doubleblind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534-1540
38. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095- 2101.